Shares of Eli Lilly (NYSE: LLY), the pharmaceuticals giant and maker of the Mounjaro and Zepbound weight loss drugs, saw its ...

This will be the first time the option has been taken up since it was introduced at the beginning of 2025, under the Medical ...

Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage ...

Eli Lilly's experimental oral pill, orforglipron, shows promise in obesity treatment, with participants experiencing an ...

There has been a 27% YoY increase in sales of weight-loss drugs, especially after the launch of Mounjaro and Novo Nordisk's ...

Eli Lilly and Company (NYSE:LLY) is one of the top most profitable NYSE stocks to buy now. On August 7, Leerink downgraded Eli Lilly and Company (NYSE:LLY) to Market Perform from Outperform with a ...

A mum who admitted that she has illegally put her 13-year-old child on Mounjaro weight loss jabs has spoken out on why she ...

A transformative moment in the global fight against obesity has emerged with the announcement of positive topline results ...

A study found jabs were linked to a 'modestly increased risk' of diabetic retinopathy-a condition caused by damage to blood ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

There's been an all-out push by the drug regulators and media to get every adult and child on Ozempic, a drug which causes temporary weight loss and harms the majority of recipients. Here, two leading ...

The program will offer pathways into genetic engineering, personalized medicine, cell and gene therapy, soil and water remediation and sustainable agriculture.